IITRI provides preclinical programs to evaluate the safety of small molecule drugs and biologics that fully support IND/NDA submissions of new drug candidates. We have extensive experience in GLP-compliant repeat-dose and nonclinical safety pharmacology studies in rats, minipigs, ferrets, dogs, and nonhuman primates. We have specialized expertise in inhalation toxicology, including aerosol generation of liquids, powders, and solids or use of inhalation devices. We also specialize in infectious disease vaccine, antiviral, and antimicrobial development, with BSL-2 and BSL-3 facilities for challenge studies including aerosol infection models. We cater to startup to mid-size biopharma, with our highly interactive study design and execution style, and access to PhD/DABT study directors.